



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ :	C12N 15/10, 15/86, C12Q 1/68, G01N 33/68	A1	(11) International Publication Number: WO 96/38553
(21) International Application Number:	PCT/DK96/00231		(43) International Publication Date: 5 December 1996 (05.12.96)
(22) International Filing Date:	31 May 1996 (31.05.96)		
(30) Priority Data:	0629 95 2 June 1995 (02.06.95)	DK	
(71) Applicant (<i>for all designated States except US</i>):	MOURITSEN & ELSNER A/S [DK/DK]; Lersø Parkallé 40, DK-2100 Copenhagen Ø (DK).		(74) Agent: HOFMAN-BANG & BOUTARD, LEHMANN & REE A/S; Adelgade 15, DK-1304 Copenhagen K (DK).
(72) Inventors; and			(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(75) Inventors/Applicants (<i>for US only</i>):	JENSEN, Martin, Roland [DK/DK]; Sydkrænten 6, DK-2840 Holte (DK). PEDERSEN, Finn, Skou [DK/DK]; Præstehaven 47, DK-8210 Aarhus V (DK). MOURITSEN, Søren [DK/DK]; Lindvangsvej 24, DK-3460 Birkerød (DK). HINDERSSON, Peter [DK/DK]; Jerichausgade 3, DK-1777 Copenhagen V (DK). DUCH, Mogens [DK/DK]; Elmevej 4, DK-8240 Riskskov (DK). SØRENSEN, Michael, Schandorf [DK/DK]; Viborgvej 33, 1. tv., DK-8000 Aarhus (DK). DALUM, Iben [DK/DK]; Olgasvej 13, DK-2970 Hørsholm (DK). LUND, Anders, Henrik [DK/DK]; Rosenkrantzgade 1, DK-8000 Aarhus C (DK).		

(54) Title: A METHOD FOR IDENTIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES AND NUCLEIC ACIDS


(57) Abstract

Biologically active peptides and nucleic acids are identified by a method comprising the following steps: (a) production of a pool of appropriate vectors each containing totally or partly random DNA sequences, (b) efficient transduction of said vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell, (c) screening of said transduced cells to see whether some of them have changed a certain phenotypic trait, (d) selection and cloning of said changed cells, (e) isolation and sequencing of the vector DNA in said phenotypically changed cells, and (f) deducing the ribonucleic acid and peptide sequences from the DNA sequence. The peptide sequences may be introduced into or fused to a larger protein preferably an antibody molecule or a fragment thereof. This may be obtained by introducing the random DNA sequences into or fusing them to a DNA sequence encoding such larger protein.

PCR manipulatable vector



Vector RNA transcript in packaging cells



Integrated vector DNA in target cells

